These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 26923902)

  • 21. Epigenomes as therapeutic targets.
    Hamm CA; Costa FF
    Pharmacol Ther; 2015 Jul; 151():72-86. PubMed ID: 25797698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role dietary of bioactive compounds on the regulation of histone acetylases and deacetylases: a review.
    Vahid F; Zand H; Nosrat-Mirshekarlou E; Najafi R; Hekmatdoost A
    Gene; 2015 May; 562(1):8-15. PubMed ID: 25701602
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer treatment of the future: inhibitors of histone methyltransferases.
    Spannhoff A; Sippl W; Jung M
    Int J Biochem Cell Biol; 2009 Jan; 41(1):4-11. PubMed ID: 18773966
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mass spectrometry in epigenetic research.
    Beck HC
    Methods Mol Biol; 2010; 593():263-82. PubMed ID: 19957154
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chromatin-modifying enzymes as therapeutic targets--Part 1.
    Keppler BR; Archer TK
    Expert Opin Ther Targets; 2008 Oct; 12(10):1301-12. PubMed ID: 18781828
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chromatin modifications (acetylation/ deacetylation/ methylation) as new targets for HIV therapy.
    Varier RA; Kundu TK
    Curr Pharm Des; 2006; 12(16):1975-93. PubMed ID: 16787242
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histone modifying enzymes and cancer: going beyond histones.
    Zhang K; Dent SY
    J Cell Biochem; 2005 Dec; 96(6):1137-48. PubMed ID: 16173079
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TR-FRET cellular assays for interrogating posttranslational modifications of histone H3.
    Machleidt T; Robers MB; Hermanson SB; Dudek JM; Bi K
    J Biomol Screen; 2011 Dec; 16(10):1236-46. PubMed ID: 21972037
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation.
    Scott SA; Dong WF; Ichinohasama R; Hirsch C; Sheridan D; Sanche SE; Geyer CR; Decoteau JF
    Leuk Res; 2006 Jan; 30(1):69-76. PubMed ID: 16043219
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Linking epigenetics to lipid metabolism: focus on histone deacetylases.
    Ferrari A; Fiorino E; Giudici M; Gilardi F; Galmozzi A; Mitro N; Cermenati G; Godio C; Caruso D; De Fabiani E; Crestani M
    Mol Membr Biol; 2012 Nov; 29(7):257-66. PubMed ID: 23095054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histone deacetylase inhibitors target diabetes via chromatin remodeling or as chemical chaperones?
    Lawless MW; O'Byrne KJ; Gray SG
    Curr Diabetes Rev; 2009 Aug; 5(3):201-9. PubMed ID: 19689255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. How do we improve histone deacetylase inhibitor drug discovery?
    Hamze A
    Expert Opin Drug Discov; 2020 May; 15(5):527-529. PubMed ID: 32116055
    [No Abstract]   [Full Text] [Related]  

  • 33. Epigenetics, DNA methylation, and chromatin modifying drugs.
    Szyf M
    Annu Rev Pharmacol Toxicol; 2009; 49():243-63. PubMed ID: 18851683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid.
    Kelly WK; Marks PA
    Nat Clin Pract Oncol; 2005 Mar; 2(3):150-7. PubMed ID: 16264908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trichostatin-A induces differential changes in histone protein dynamics and expression in HeLa cells.
    Rao J; Bhattacharya D; Banerjee B; Sarin A; Shivashankar GV
    Biochem Biophys Res Commun; 2007 Nov; 363(2):263-8. PubMed ID: 17869223
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chromium cross-links histone deacetylase 1-DNA methyltransferase 1 complexes to chromatin, inhibiting histone-remodeling marks critical for transcriptional activation.
    Schnekenburger M; Talaska G; Puga A
    Mol Cell Biol; 2007 Oct; 27(20):7089-101. PubMed ID: 17682057
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HDAC inhibition through valproic acid modulates the methylation profiles in human embryonic kidney cells.
    Ganai SA; Kalladi SM; Mahadevan V
    J Biomol Struct Dyn; 2015; 33(6):1185-97. PubMed ID: 25012937
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Cohesin loading factor NIPBL recruits histone deacetylases to mediate local chromatin modifications.
    Jahnke P; Xu W; Wülling M; Albrecht M; Gabriel H; Gillessen-Kaesbach G; Kaiser FJ
    Nucleic Acids Res; 2008 Nov; 36(20):6450-8. PubMed ID: 18854353
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
    Liu S; Klisovic RB; Vukosavljevic T; Yu J; Paschka P; Huynh L; Pang J; Neviani P; Liu Z; Blum W; Chan KK; Perrotti D; Marcucci G
    J Pharmacol Exp Ther; 2007 Jun; 321(3):953-60. PubMed ID: 17389244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Small molecule modulators of histone acetylation and methylation: a disease perspective.
    Selvi BR; Mohankrishna DV; Ostwal YB; Kundu TK
    Biochim Biophys Acta; 2010; 1799(10-12):810-28. PubMed ID: 20888936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.